Figure S1. Analysis of immune‑associated gene expression levels regulated by DDX41. (A) Top ten GO terms of upregulated gene sets. (B) Top ten KEGG pathways of downregulated gene sets. (C) Hierarchical clustering of the expression of immune‑associ-ated differentially expressed genes regulated by DDX41 overexpression in HeLa cells compared with Ctrl. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DDX41, DEAD‑box helicase 41; Ctrl, control.

Figure S2. Kaplan‑Meier curves of DDX41 upregulated genes in patients with cervical cancer. (A) Survival analysis of two genes in the Gene Expression Profiling Interactive Analysis databases of cervical and endocervical squamous carcinoma (cut‑off point based on the median method). (B) Images of the DDX41 distribution (n=3). DDX41, DEAD‑box helicase 41; HR, hazard ratio.

Figure S3. Schematic diagrams depicting the structures of AS1 (purple) and AS2 (green). Boxes indicate exon sequences; hori-zontal line indicates intron sequences. RNA‑seq quantification and qPCR validation of ASEs. The changed ratio of ASEs in RNA‑seq were calculated using the formula: AS1 junction reads/AS1 junction reads + AS2 junction reads. The altered ratio of ASEs in qPCR was calculated using the formula: AS1 transcripts level/AS2 transcripts level. Con, control; OE‑DDX41, overex-pression DEAD‑box helicase 41; RNA‑seq, RNA‑sequencing; qPCR, quantitative PCR.

Tabl

e SI

. Prim

ers u

sed

in re

vers

e tra

nscr

iptio

n-qu

antit

ativ

e PC

R.

A, O

vere

xpre

ssio

n

Gen

e Fo

rwar

d pr

imer

(5'→

3')

Rev

erse

prim

er (5

'→3'

)

DD

X41

GTA

TCC

CA

CC

AC

CC

ATC

AA

G

AC

CA

GTG

TCTT

GC

CTG

AA

CC

B, D

iffer

entia

lly e

xpre

ssed

gen

es

Gen

e Fo

rwar

d pr

imer

R

ever

se p

rimer

IL12

A AT

TGA

GAT

GG

GA

GG

ATTG

C

AG

AC

ATAT

TGTC

CA

GG

CT

CD

22

GG

CC

TTTT

CC

AC

CTC

ATA

G

GAT

CG

GAT

AC

CC

ATA

GC

CD

177

AC

GG

AG

GC

CA

AG

GA

CC

AG

C

CA

AA

GC

GG

GA

GG

GA

GTT

CSF

2 G

AC

CTG

CC

TAC

AG

AC

CC

G

GG

CC

CTT

GA

GC

TTG

GTG

ASE

LPLG

G

CC

GTC

AG

TCG

AG

TTG

TC

CA

GC

AG

CTA

TGG

AG

ATA

CA

GTN

FRSF

1B

GC

AC

TCG

GG

AA

CA

GA

AC

C

GC

AC

CC

CTC

CTG

CTT

GC

TH

SPA1

A C

GTT

GTC

CC

AA

GG

CTT

CC

C

TGTC

GG

CTC

CG

CTC

TGA

HSP

A1B

GC

TGA

AC

CC

GC

AG

AA

CA

C

TCC

TCG

GG

GTA

GA

ATG

CC

HSP

A6

CG

GTG

CA

GTC

GG

AC

ATG

A

TCTC

CTC

GG

GG

TAG

AA

CG

HLA

-DM

B G

CC

ATC

TTAT

TCTC

CTC

TG

TGG

AA

AG

CA

CC

TGTC

TGT

HLA

-DO

B AT

CC

AC

GG

CC

TGTC

TGC

T G

TGAT

GTG

GG

GAT

GTT

TGH

LA-G

TC

TAC

CC

TGC

GG

AG

ATC

A

CTC

CA

GA

AG

GC

AC

CA

CC

AH

PV18

-E6

ATA

AG

GTG

CC

TGC

GG

TGC

C

TGC

GTC

GTT

GG

AG

TCG

TTC

HPV

18-E

7 G

AG

CA

CG

AC

AG

GA

AC

GA

CT

GG

GC

TGG

TAA

ATG

TTG

ATG

ATH

PV18

-L1

CA

GG

TGG

TGG

CA

ATA

AG

CA

GG

A

TGG

CG

GC

ATG

GG

AA

CTT

TCA

GG

APD

H

GG

TCG

GA

GTC

AA

CG

GAT

TTG

G

GA

AG

ATG

GTG

ATG

GG

ATTT

C

C, A

ltern

ativ

e sp

licin

g ev

ents

Gen

e Fo

rwar

d pr

imer

R

ever

se p

rimer

CFD

A

S1

TGG

AG

GA

CG

CG

GC

CG

AC

GG

G

AG

CA

GG

AG

GTC

GTG

GTC

G

AS2

G

GTC

CC

CA

GG

GG

CC

GA

CG

GG

PGLY

RP1

AS1

C

CA

ATTC

TGG

ATG

AG

GTG

GTA

A

AC

TAC

ATG

GAT

CG

GG

TGC

C

AS2

CC

TCC

TCC

AG

ATC

GG

GTG

CC

NEA

TC3_

A3SS

A

S1

CA

GC

AC

TCA

AC

TCA

AG

CA

G

TAA

AC

AA

ATC

ATC

ATC

TAA

A

S2

TA

GG

TCTC

AA

CAT

CAT

CTA

AN

EATC

3_M

EX

AS1

A

S2

CA

GC

AC

TCA

AC

TCA

AG

CA

AT

AA

ATTG

GTC

ATC

ATC

TAA

TA

GG

TCTC

AA

CAT

CAT

CTA

A

Tabl

e SI

. Con

tinue

d.

C, A

ltern

ativ

e sp

licin

g ev

ents

Gen

e Fo

rwar

d pr

imer

R

ever

se p

rimer

NO

D1

AS1

TA

CG

CTG

AG

TCTG

AG

AA

CA

G

CTA

CTG

CA

AC

GC

CTG

CTC

A

S2

GA

CC

TCTG

CC

CTG

AG

AA

CA

GZC

3HAV

1 A

S1

AA

GC

GG

AC

AA

CC

CTT

AC

A

CTT

GTT

AA

CG

ATTC

TTTA

TC

AS2

TC

TGC

TCA

GTA

TTC

TTTA

TCIF

ITM

1 A

S1

GA

CA

AG

TGA

GC

CA

GA

AG

ATG

TT

GA

AC

AG

GG

AC

CA

GA

CG

A

S2

TCC

CC

AA

AG

CC

CA

GA

AG

ATG

TA

NK

A

S1

TGG

AG

AA

GA

GA

CC

TGTC

ATT

CTG

CC

GG

AA

GG

CTT

CAT

A

AS2

C

AA

AC

GA

GA

GA

CC

TGTC

ATT

NLR

X1-1

A

S1

CTG

CC

TGA

AG

GA

CA

GA

AG

TC

TCG

CTG

GA

GTG

CTC

TTC

T

AS2

G

CA

GC

CG

CG

GG

AC

AG

AA

GTC

N

LRX1

-2

AS1

C

CG

CTG

CC

AG

GA

CA

GA

AG

TC

TCG

CTG

GA

GTG

CTC

TTC

T

AS2

G

CG

GG

CG

GA

GG

AC

AG

AA

GTC

C

HID

1 A

S1

GTC

CA

GA

GG

GC

TGC

ATG

TCA

A

GC

CC

TGC

CC

AG

TCC

CC

TGT

A

S2

GG

GTG

GA

AAT

CTG

CAT

GTC

A

Table SII. Summary of RNA-sequencing reads used.

Sample Raw reads Clean reads Paired-end reads Total mappeda Total uniquely mappedb Splice readsc

DDX41_1st 82863280 79800968 36767980 69908587 67381207 27164706 (90.62%) (96.38%) (40.31%)DDX41_2nd 87014568 83839108 36659857 73033917 70304018 27599947 (90.06%) (96.26%) (39.26%)Ctrl_1st 79477058 76304335 38572300 67176989 64837664 26594525 (91.35%) (96.52%) (41.02%)Ctrl_2nd 79182390 76036977 40548512 66508088 64019512 25577536 (90.71%) (96.26%) (39.95%)

aPercentage of paired-end reads mapped to the genome. bPercentage of  unique  reads  mapping out of the total  mapped  reads. cPercentage of uniquely mapped reads mapped to splice site. DDX41, DEAD-box helicase 41; Ctrl, control.

Table SIII. Numbers of genes expressed in each sample.

Expressed genes ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑Sample FPKM>0 FPKM≥1

OECtrl_1st 24,499 13,173OECtrl_2nd 25,045 13,164DDX41_1st 24,618 12,892DDX41_2nd 24,440 12,885Totalgenes 28,914

OE,overexpression;Ctrl,control;DDX41,DEAD-boxhelicase41;FPKM,fragmentsperkilobaseoftranscriptpermillion.